Case report: retinopathy associated with the use of hair dye aromatic amines
Presentation closely resembled mitogen-activated extracellular signal-regulated kinase inhibitor–associated retinopathy
Industry updates from Floretina ICOOR 2024
The annual meeting brought fourth announcements and insights from companies in the retina care space
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
Dr Wykoff addressed the top three questions retina specialists have about retinal non-perfusion
Don’t miss our editorial advisory board members at the Floretina/ICOOR meeting
EAB members from Ophthalmology Times Europe, Ophthalmology Times and Modern Retina are presenting in Florence
New wet AMD therapeutics seek to improve visual outcomes beyond the current standard of care
Breakthrough technologies are raising the ceiling for functional visual outcomes
The Floretina ICOOR meeting begins in Florence, Italy
What to expect from 4 days in the Fortezza de Basso
Adapting our understanding of cerebral visual impairment
The differential recruitment of the dorsal and ventral visual streams
Ethnic background has an impact on glaucoma outcomes
Gauging patient perceptions in an ethnically diverse UK cohort
Recyclable ophthalmic instrument company HASA OPTIX receives B Corporation certification
The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries
Factors of ocular pain and dry eye disease associated with anxiety and COVID-19
The authors analysed severity and frequency of ocular pain among patients with DED living in altitudes above 2,500 meters during the COVID-19 pandemic
New study examines RNFL changes and association with BMI, tobacco and alcohol use
A higher body mass index was protective against glaucoma progression, while patients who were underweight had significantly faster rates of structural loss
The deep dish on all things ophthalmology at this year's AAO meeting
The annual meeting held in Chicago, Illinois, featured new data and best practices for patient-centred care
EMA grants orphan medicinal product designation for OCU410ST (Ocugen)
OCU410ST is indicated for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa and cone-rod dystrophy 3 (CORD3)
Ocular tuberculosis and relapse rates for recurrence of uveitis
Uveitic relapses primarily manifest as anterior uveitis, the authors said
On the 75th anniversary of the IOL, modern surgeons pay tribute
At the ESCRS meeting, Sir Harold Ridley’s legacy was put on display in a pop-up museum installation
Arctic Vision partners with Santen Pharmaceutical Co., Ltd. to commercialise ARVN001 in China
ARVN001 is indicated for the treatment of uveitic macular oedema and certain other ophthalmic indications
Incidence of microbial keratitis associated with overnight orthokeratology
The incidence was comparable to that of daily wear soft contact lenses
European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis
OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases
CHMP issues positive opinion for marketing authorisation of aflibercept biosimilar FYB203 (Formycon)
The positive opinion marks a key regulatory step towards the approval of FYB203, which will go by the trade names AHZANTIVE and Baiama in the European Union
US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)
The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration
NHS introduces OCT programme to reduce annual hospital visits for patients with diabetes
Optical coherence tomography will be in all eye care services by October 2025
Choosing the specular microscope that fits your clinic
Assessing two devices in a real-world setting
European Commission grants marketing authorisation for aflibercept biosimilar Afqlir (Sandoz Group)
The biosimilar to reference aflibercept (Eylea, Bayer AG) is indicated to treat retinal diseases including neovascular age-related macular degeneration
Canada passes National Strategy for Eye Care Act
A coalition of eye health advocacy groups vocalised support for the legislation
How a gene-agnostic approach opens doors to new therapeutics
Arun Upadhyay, PhD, discusses new study findings from trials of OCU400 (Ocugen)
US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy
HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration
Zooming in on geographic atrophy with OCT-based AI
New analysis brings disease progression and therapeutics into focus
Adding aromatherapy to recovery protocol may decrease postoperative anxiety and pain
Following oculoplastic surgery, patients who underwent aromatherapy had shorter stays in the post-anesthesia care unit
Innovation and the clinician scientist
Collaboration and outside-the-box thinking present significant opportunities for science and industry
Excellence across the board at the 2024 EURETINA congress
This year’s Barcelona meeting brought together award-winning research data and leaders in the retina field
